News

This is the third safety incident in the IGNITE DMD clinical trial that has resulted in a clinical hold since its inception in 2017.

The director of Centers for Neuropsychology and Neuroscience Research and Traumatic Brain Injury Research at Kessler Foundation spoke to the use of strategy training and how it mirrors real-life situations for patients with MS and TBI.

The medical director of the Deep Brain Stimulation Program at Cleveland Clinic shared his perspective on deep brain stimulation and its impact on the treatment landscape.

An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.

Patients with spinal muscular atrophy types 2 or 3 saw improvements in motor function after receiving risdiplam; data will be presented at an upcoming medical congress.

The director of the Epilepsy Center and vice chair of Neurological Institute for Strategy and Development at Cleveland Clinic detailed how researchers are working to utilize a biomarker to enhance epilepsy surgery.

Study findings have shown sustained improvements in seizure-freedom rates and functional outcomes in a cohort of adults that mirror prior findings in pediatric populations.

The comprehensive aggressive migraine protocol (CAMP), combining DHE infusion and multidisciplinary care, significantly reduced headache intensity and frequency among other measures in a small group of patients.

The associate professor at Leiden University Medical Center detailed how palliative care can be used more effectively in patients with dementia.

Neurology News Network for the week ending November 9, 2019.

EIP Pharma also announced results from the REVERSE-SD study that examined neflamapimod in early stage Alzheimer disease.

The robotic platform used in various neurosurgeries was identified for a class 1 recall due to a software error which can lead to robotic arm malfunction.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine provided her perspective on the differences in OSA prevalence for men and women and how adherence to CPAP remains a challenge.

The medical director of the Deep Brain Stimulation Program at Cleveland Clinic shared his insight into the current state of affairs in the Parkinson disease treatment paradigm.

The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic relayed his excitement for a new advanced imaging tool that could change how epilepsy specialists diagnose and treat the disease.

The phase 2/3 trials will end after a futility analysis suggested that the drug is not likely to show a clinical benefit.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic offered insight into the challenges that have plagued physicians in identifying biomarkers for Lewy body dementia.

The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared his unique perspective on spinal cord injury and the work he and colleagues are doing to alleviate its challenges.

Imad Najm, MD, details how advanced telemedicine technology has created a paradigm shift in the way physicians see and treat patients at Cleveland Clinic and around the world.

UCB’s intranasal midazolam spray (Nayzilam), an FDA-approved therapy for seizure clusters, has shown success and rapid efficacy in status epilepticus, with treatment effect occurring approximately 4 to 5 minutes post-administration.

Data show patients with high frequency episodic migraine are comparable to those with chronic migraine in regard to chronicity and disability.

The director of the Epilepsy Center at Cleveland Clinic spoke about the challenges faced when identifying focal cortical dysplasia.

A new analysis from the phase 3 HALO development program showed that Teva’s CGRP inhibitor fremanezumab (Ajovy) separated from placebo by Day 2 posttreatment, suggesting not only rapid clinical improvement, but the potential to positively impact treatment adherence.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the available options for Parkinson dementia and how they compare in Alzheimer, as well as the ongoing development in Alzheimer.

The Green Valley agent, which is derived from seaweed, showed significant improvements in ADAS-Cog scores over placebo and is anticipated to make its debut on the market in China in late 2019.

Study results suggest that as many as 20% of patients may be nonadherent to medication regimens, with youth having the strongest association with intentional nonadherence.

The neurologist at Thomas Jefferson University Hospitals discussed the pros and cons of supplemental drugs used to reduce off time in patients with Parkinson disease.

The 2019 update to the 2018 guidelines clarifies prior recommendations and takes into consideration new clinical trial data to offer a comprehensive guide for treatment, from symptom onset through 2 weeks after acute ischemic stroke.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the ground that has been made in treating dementia, and how nuance in diagnosis can provide a possible leg up for physicians.

The neurologist at Cleveland Clinic outlines the need to better understand the biology of progressive MS in order to make substantial headway in its treatment.